S&P Futures
3,806.50+16.00(+0.42%)Dow Futures
30,905.00+77.00(+0.25%)Nasdaq Futures
13,092.75+107.25(+0.83%)
Adicet Bio, Inc. (ACET)
Chart Events
Performance Outlook
| Previous Close | 13.10 |
| Open | 13.14 |
| Bid | 12.10 x 800 |
| Ask | 20.00 x 1800 |
| Day's Range | 12.78 - 13.50 |
| 52 Week Range | 6.02 - 21.70 |
| Volume | 52,629 |
| Avg. Volume | 55,733 |
| Market Cap | 264.798M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.90 |
| Earnings Date | Nov 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.25 |
Fair Value
Related Research
- GlobeNewswire
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January. Details of the events are as follows:H.C. Wainwright Bioconnect 2021 Conference The presentation will be available for on-demand viewing starting January 11, 2021 at 6:00 AM ET.B. Riley Securities' Oncology Investor Conference Fireside chat on January 20, 2021 at 3:30 PM ET.A replay of the pre-recorded H.C. Wainwright presentation can be accessed on January 11, 2021 in the investors section of the Company’s website, and a live webcast of the B. Riley presentation can be accessed in the same section of the Company’s website. About Adicet Bio, Inc.Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge abowdidge@adicetbio.comJanhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
- Simply Wall St.
We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc. Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge abowdidge@adicetbio.comJanhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
